{
    "abstract": "Background: Two conserved pneumococcal proteins, pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD), combined with 10 polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in two investigational pneumococcal vaccine (PHiD-CV/dPly/PhtD) formulations were immunogenic and well-tolerated when administered to Gambian children. Here, we report immunogenicity of the polysaccharide conjugates, and immunogenicity and reactogenicity of co-administered routine vaccines. Methods: In this phase II, controlled, observer-blind, single-centre study, healthy infants aged 8\u201310 weeks were randomised (1:1:1:1:1:1) to six groups. Four groups received 3+0 schedule (2-3-4 months [M]) of PHiD-CV/dPly/PhtD (10 or 30 \u00b5g of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine; and two groups received 2+1 schedule (2-4-9 M) of PHiD-CV/dPly/PhtD (30 \u00b5g of each protein) or PHiD-CV. All infants received diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b (DTPw-HBV/Hib) and oral trivalent polio vaccines (OPV) at 2-3-4 M, and measles, yellow fever, and OPV vaccines at 9 M. We evaluated immune responses at 2-5-9-12 M; and reactogenicity 0\u20133 days post-vaccination. Results: 1200 infants were enrolled between June 2011 and May 2012; 1152 completed the study. 1 M post-primary vaccination, for each PHiD-CV serotype except 6B and 23F, \u226597.4% (3+0 schedule) and \u226596.4% (2+1 schedule) of infants had antibody concentrations \u22650.2 \u03bcg/mL. Immune responses were comparable between groups within the same vaccination schedules. Observed antibody geometric mean concentrations (GMCs) increased by 1 M post-primary vaccination compared to pre-vaccination. In the following months, GMCs and opsonophagocytic activity titres waned, with an increase post-booster for the 2+1 schedule. Immune responses to protein D and, DTPw-HBV/Hib, OPV, measles, and yellow fever vaccines were not altered by co-administration with pneumococcal proteins. Reactogenicity of co-administered vaccines was comparable between groups and did not raise concerns. Conclusion: Immune responses to the 10 PHiD-CV polysaccharide conjugates and co-administered vaccines were not altered by addition of dPly and PhtD. ClinicalTrials.gov identifier NCT01262872.",
    "author_highlights": [
        {
            "endOffset": 29478,
            "sentence": "PHiD-CV/dPly/PhtD contained 10 polysaccharide conjugates and 2 pneumococcal proteins.",
            "startOffset": 29393
        },
        {
            "endOffset": 29564,
            "sentence": "Immune response to PHiD-CV antigens did not appear altered by dPly and PhtD proteins.",
            "startOffset": 29479
        },
        {
            "endOffset": 29650,
            "sentence": "Immune response persistence at 12 months of age was higher for 2+1 than 3+0 schedule.",
            "startOffset": 29565
        },
        {
            "endOffset": 29734,
            "sentence": "PHiD-CV/dPly/PhtD did not alter immunogenicity of co-administered routine vaccines.",
            "startOffset": 29651
        },
        {
            "endOffset": 29805,
            "sentence": "No concerns were raised on reactogenicity of co-administered vaccines.",
            "startOffset": 29735
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [],
            "firstpage": "129",
            "issn": "00498114",
            "lastpage": "144",
            "pmid": "24340399",
            "pub_year": 2012,
            "title": "Pneumococcal vaccines WHO position paper--2012.",
            "volume": "87"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Hope L.",
                    "initial": "H.L.",
                    "last": "Johnson"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Deloria-Knoll"
                },
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Sonia K.",
                    "initial": "S.K.",
                    "last": "Stoszek"
                },
                {
                    "first": "Laura Freimanis",
                    "initial": "L.F.",
                    "last": "Hance"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Reithinger"
                },
                {
                    "first": "Larry R.",
                    "initial": "L.R.",
                    "last": "Muenz"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                }
            ],
            "doi": "10.1371/journal.pmed.1000348",
            "issn": "15491277",
            "pmid": "20957191",
            "pub_year": 2010,
            "title": "Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project",
            "volume": "7"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Lexau"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Farley"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hadler"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Nancy M.",
                    "initial": "N.M.",
                    "last": "Bennett"
                },
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Reingold"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Thomas"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Schaffner"
                },
                {
                    "first": "Allen S.",
                    "initial": "A.S.",
                    "last": "Craig"
                },
                {
                    "first": "Philip J.",
                    "initial": "P.J.",
                    "last": "Smith"
                },
                {
                    "first": "Bernard W.",
                    "initial": "B.W.",
                    "last": "Beall"
                },
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                },
                {
                    "first": "Matthew R.",
                    "initial": "M.R.",
                    "last": "Moore"
                }
            ],
            "doi": "10.1086/648593",
            "firstpage": "32",
            "issn": "00221899",
            "lastpage": "41",
            "pmid": "19947881",
            "pub_year": 2010,
            "title": "Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine",
            "volume": "201"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Farley"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hadler"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Nancy M.",
                    "initial": "N.M.",
                    "last": "Bennett"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Lynfield"
                },
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Reingold"
                },
                {
                    "first": "Paul R.",
                    "initial": "P.R.",
                    "last": "Cieslak"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Delois",
                    "initial": "D.",
                    "last": "Jackson"
                },
                {
                    "first": "Richard R.",
                    "initial": "R.R.",
                    "last": "Facklam"
                },
                {
                    "first": "James H.",
                    "initial": "J.H.",
                    "last": "Jorgensen"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuchat"
                }
            ],
            "doi": "10.1056/NEJMoa022823",
            "firstpage": "1737",
            "issn": "00284793",
            "lastpage": "1746",
            "pmid": "12724479",
            "pub_year": 2003,
            "title": "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine",
            "volume": "348"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Lucia Helena",
                    "initial": "L.H.",
                    "last": "De Oliveira"
                },
                {
                    "first": "Luiz Antonio B.",
                    "initial": "L.A.B.",
                    "last": "Camacho"
                },
                {
                    "first": "Evandro S.F.",
                    "initial": "E.S.F.",
                    "last": "Coutinho"
                },
                {
                    "first": "Martha S.",
                    "initial": "M.S.",
                    "last": "Martinez-Silveira"
                },
                {
                    "first": "Ana Flavia",
                    "initial": "A.F.",
                    "last": "Carvalho"
                },
                {
                    "first": "Cuauhtemoc",
                    "initial": "C.",
                    "last": "Ruiz-Matus"
                },
                {
                    "first": "Cristiana M.",
                    "initial": "C.M.",
                    "last": "Toscano"
                }
            ],
            "doi": "10.1371/journal.pone.0166736",
            "issn": "19326203",
            "pmid": "27941979",
            "pub_year": 2016,
            "title": "Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: A systematic review",
            "volume": "11"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.03.107",
            "firstpage": "2959",
            "issn": "0264410X",
            "lastpage": "2961",
            "pmid": "27083428",
            "pub_year": 2016,
            "title": "Status of research and development of pediatric vaccines for Streptococcus pneumoniae",
            "volume": "34"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Amy Sarah",
                    "initial": "A.S.",
                    "last": "Ginsburg"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Farukh M.",
                    "initial": "F.M.",
                    "last": "Khambaty"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1586/erv.12.5",
            "firstpage": "279",
            "issn": "14760584",
            "lastpage": "285",
            "pmid": "22380821",
            "pub_year": 2012,
            "title": "Issues and challenges in the development of pneumococcal protein vaccines",
            "volume": "11"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Seiberling"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Brookes"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Ochs"
                },
                {
                    "first": "Kerry",
                    "initial": "K.",
                    "last": "Go"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Lashley"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.080",
            "firstpage": "7455",
            "issn": "0264410X",
            "lastpage": "7460",
            "pmid": "23131206",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults",
            "volume": "30"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Branda",
                    "initial": "B.",
                    "last": "Hu"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Corde"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Pouzet"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Zimmermann"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.005",
            "firstpage": "327",
            "issn": "0264410X",
            "lastpage": "333",
            "pmid": "23153437",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults",
            "volume": "31"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Cathy",
                    "initial": "C.",
                    "last": "Maes"
                },
                {
                    "first": "Fien",
                    "initial": "F.",
                    "last": "De Boever"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.02.052",
            "firstpage": "6838",
            "issn": "0264410X",
            "lastpage": "6846",
            "pmid": "24607003",
            "pub_year": 2014,
            "title": "Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study",
            "volume": "32"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Pazdiora"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.03.066",
            "firstpage": "3025",
            "issn": "0264410X",
            "lastpage": "3034",
            "pmid": "24699466",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial",
            "volume": "32"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Leszek",
                    "initial": "L.",
                    "last": "Szenborn"
                },
                {
                    "first": "Sven Arne",
                    "initial": "S.A.",
                    "last": "Silfverdal"
                },
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Piotr",
                    "initial": "P.",
                    "last": "Albrecht"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Asparuh",
                    "initial": "A.",
                    "last": "Gardev"
                },
                {
                    "first": "Yue",
                    "initial": "Y.",
                    "last": "Song"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.07.008",
            "firstpage": "4603",
            "issn": "0264410X",
            "lastpage": "4611",
            "pmid": "28729019",
            "pub_year": 2017,
            "title": "Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants",
            "volume": "35"
        },
        "b0070": null,
        "b0075": null,
        "b0080": {
            "authors": [
                {
                    "first": "Aderonke",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "Martin O.C.",
                    "initial": "M.O.C.",
                    "last": "Ota"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Ezra O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "Yauba",
                    "initial": "Y.",
                    "last": "Saidu"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Owiafe"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Ceesay"
                },
                {
                    "first": "Archibald",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Olumuyiwa",
                    "initial": "O.",
                    "last": "Owolabi"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Isatou",
                    "initial": "I.",
                    "last": "Drammeh"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Devos"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Schoonbroodt"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.071",
            "firstpage": "2531",
            "issn": "0264410X",
            "lastpage": "2542",
            "pmid": "28389097",
            "pub_year": 2017,
            "title": "Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study",
            "volume": "35"
        },
        "b0085": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "M. O.",
                    "initial": "M.O.",
                    "last": "Ota"
                },
                {
                    "first": "E. O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Owiafe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1080/21645515.2015.1111496",
            "firstpage": "393",
            "issn": "21645515",
            "lastpage": "402",
            "pmid": "26618243",
            "pub_year": 2016,
            "title": "Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134\u00a0years: A phase II randomized study",
            "volume": "12"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                }
            ],
            "doi": "10.1128/CVI.00289-09",
            "firstpage": "134",
            "issn": "15566811",
            "lastpage": "142",
            "pmid": "19889940",
            "pub_year": 2010,
            "title": "Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines",
            "volume": "17"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Libutti"
                },
                {
                    "first": "Lorna B.",
                    "initial": "L.B.",
                    "last": "Pais"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Dykes"
                },
                {
                    "first": "Porter",
                    "initial": "P.",
                    "last": "Anderson"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Whitin"
                },
                {
                    "first": "Harry L.",
                    "initial": "H.L.",
                    "last": "Keyserling"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                }
            ],
            "firstpage": "415",
            "issn": "1071412X",
            "lastpage": "422",
            "pmid": "9220157",
            "pub_year": 1997,
            "title": "Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells",
            "volume": "4"
        },
        "b0100": null,
        "b0105": {
            "authors": [
                {
                    "first": "Carla Magda Allan S.",
                    "initial": "C.M.A.S.",
                    "last": "Domingues"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Ernesto Issac",
                    "initial": "E.I.",
                    "last": "Montenegro Renoiner"
                },
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "de Cunto Brandileone"
                },
                {
                    "first": "Brendan",
                    "initial": "B.",
                    "last": "Flannery"
                },
                {
                    "first": "Lucia Helena",
                    "initial": "L.H.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Jo\u00e3o Barberino",
                    "initial": "J.B.",
                    "last": "Santos"
                },
                {
                    "first": "Jos\u00e9 C\u00e1ssio",
                    "initial": "J.C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Regina Coeli Magalh\u00e3es",
                    "initial": "R.C.M.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Marluce Aparecida Assun\u00e7\u00e3o",
                    "initial": "M.A.A.",
                    "last": "Oliveira"
                },
                {
                    "first": "Tani Maria Schilling",
                    "initial": "T.M.S.",
                    "last": "Ranieri"
                },
                {
                    "first": "Gladys Maria",
                    "initial": "G.M.",
                    "last": "Zubaran"
                },
                {
                    "first": "Ana L\u00eddia Lima",
                    "initial": "A.L.L.",
                    "last": "Solon"
                },
                {
                    "first": "Maria Iracema",
                    "initial": "M.I.",
                    "last": "de Aguiar Patr\u00edcio"
                },
                {
                    "first": "Maria Elisa Paula",
                    "initial": "M.E.P.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "de C\u00e1ssia Vilasboas Silva"
                },
                {
                    "first": "Marlene Sera",
                    "initial": "M.S.",
                    "last": "Wille"
                },
                {
                    "first": "Pilar Gomes",
                    "initial": "P.G.",
                    "last": "Martinez"
                },
                {
                    "first": "Helena Keico",
                    "initial": "H.K.",
                    "last": "Sato"
                },
                {
                    "first": "Maria Cristina Hereny",
                    "initial": "M.C.H.",
                    "last": "Bordim"
                },
                {
                    "first": "Luzia Auxiliadora",
                    "initial": "L.A.",
                    "last": "Careli"
                },
                {
                    "first": "Vera L\u00facia",
                    "initial": "V.L.",
                    "last": "da Gl\u00f3ria Malheiros"
                },
                {
                    "first": "Zenize Rocha",
                    "initial": "Z.R.",
                    "last": "da Silva Costa"
                },
                {
                    "first": "Maria Goretti Varej\u00e3o",
                    "initial": "M.G.V.",
                    "last": "da Silva"
                },
                {
                    "first": "Cleidiane Santos",
                    "initial": "C.S.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Ataiza C\u00e9sar",
                    "initial": "A.C.",
                    "last": "Vieira"
                },
                {
                    "first": "Lucila Tacac\u00f4",
                    "initial": "L.T.",
                    "last": "Watanabe"
                },
                {
                    "first": "Glaucia Gama Rahal",
                    "initial": "G.G.R.",
                    "last": "Aires"
                },
                {
                    "first": "Robmary Matias",
                    "initial": "R.M.",
                    "last": "de Almeida"
                },
                {
                    "first": "Diana Felicia",
                    "initial": "D.F.",
                    "last": "de Ara\u00fajo Margarido"
                },
                {
                    "first": "Ana L\u00facia Stone",
                    "initial": "A.L.S.",
                    "last": "de Souza"
                },
                {
                    "first": "Samanta C.G.",
                    "initial": "S.C.G.",
                    "last": "Almeida"
                },
                {
                    "first": "Angela P.",
                    "initial": "A.P.",
                    "last": "Brand\u00e3o"
                },
                {
                    "first": "Lincoln S.",
                    "initial": "L.S.",
                    "last": "Prado"
                },
                {
                    "first": "Maria Luiza L.S.",
                    "initial": "M.L.L.S.",
                    "last": "Guerra"
                },
                {
                    "first": "Orlando Cesar",
                    "initial": "O.C.",
                    "last": "Mantese"
                },
                {
                    "first": "Eitan",
                    "initial": "E.",
                    "last": "Berezin"
                },
                {
                    "first": "Cicero",
                    "initial": "C.",
                    "last": "Dias"
                },
                {
                    "first": "Cristiana",
                    "initial": "C.",
                    "last": "Nascimento"
                },
                {
                    "first": "Joice",
                    "initial": "J.",
                    "last": "Reis"
                },
                {
                    "first": "Ana Lucia",
                    "initial": "A.L.",
                    "last": "Andrade"
                },
                {
                    "first": "Solange",
                    "initial": "S.",
                    "last": "Andrade"
                },
                {
                    "first": "Flavia",
                    "initial": "F.",
                    "last": "Lobo"
                },
                {
                    "first": "Camile",
                    "initial": "C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Eliane Castro",
                    "initial": "E.C.",
                    "last": "de Barros"
                },
                {
                    "first": "M\u00e1rcia Lopes",
                    "initial": "M.L.",
                    "last": "de Carvalho"
                },
                {
                    "first": "Elias Duarte Gon\u00e7alves",
                    "initial": "E.D.G.",
                    "last": "Correia"
                },
                {
                    "first": "Selma Lina",
                    "initial": "S.L.",
                    "last": "Suzuki"
                }
            ],
            "doi": "10.1016/S2213-2600(14)70060-8",
            "firstpage": "464",
            "issn": "22132600",
            "lastpage": "471",
            "pmid": "24726406",
            "pub_year": 2014,
            "title": "Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: A matched case-control study",
            "volume": "2"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Arto A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Jokinen"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Heta",
                    "initial": "H.",
                    "last": "Nieminen"
                },
                {
                    "first": "Esa",
                    "initial": "E.",
                    "last": "Ruokokoski"
                },
                {
                    "first": "Lotta",
                    "initial": "L.",
                    "last": "Siira"
                },
                {
                    "first": "Taneli",
                    "initial": "T.",
                    "last": "Puumalainen"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Marjan",
                    "initial": "M.",
                    "last": "Hezareh"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61854-6",
            "firstpage": "214",
            "issn": "01406736",
            "lastpage": "222",
            "pub_year": 2013,
            "title": "Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: A cluster randomised trial",
            "volume": "381"
        },
        "b0115": {
            "authors": [
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Jokinen"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Nieminen"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Syrj\u00e4nen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Ruokokoski"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Puumalainen"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "T. M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                }
            ],
            "doi": "10.1016/S2213-2600(14)70139-0",
            "firstpage": "717",
            "issn": "22132600",
            "lastpage": "727",
            "pmid": "25127244",
            "pub_year": 2014,
            "title": "Vaccine effectiveness of the pneumococcal haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: A cluster-randomised trial",
            "volume": "2"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Miguel W.",
                    "initial": "M.W.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "S\u00e1ez-Llorens"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Hector",
                    "initial": "H.",
                    "last": "Abate"
                },
                {
                    "first": "Enrique",
                    "initial": "E.",
                    "last": "Smith"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "P\u00f3sleman"
                },
                {
                    "first": "Arlene",
                    "initial": "A.",
                    "last": "Calvo"
                },
                {
                    "first": "Digna",
                    "initial": "D.",
                    "last": "Wong"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Cortes-Barbosa"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Ceballos"
                },
                {
                    "first": "Marcelo",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Sierra"
                },
                {
                    "first": "Mirna",
                    "initial": "M.",
                    "last": "Rodriguez"
                },
                {
                    "first": "Marisol",
                    "initial": "M.",
                    "last": "Troiti\u00f1o"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Carabajal"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Falaschi"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Leandro"
                },
                {
                    "first": "Maria Mercedes",
                    "initial": "M.M.",
                    "last": "Castrej\u00f3n"
                },
                {
                    "first": "Alejandro",
                    "initial": "A.",
                    "last": "Lepetic"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hausdorff"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Javier Ruiz",
                    "initial": "J.R.",
                    "last": "Gui\u00f1az\u00fa"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Ortega-Barr\u00eda"
                },
                {
                    "first": "Juan P.",
                    "initial": "J.P.",
                    "last": "Yarz\u00e1bal"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1371/journal.pmed.1001657",
            "firstpage": "1",
            "issn": "15491277",
            "lastpage": "18",
            "pmid": "24892763",
            "pub_year": 2014,
            "title": "Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial",
            "volume": "11"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Alassane",
                    "initial": "A.",
                    "last": "Dicko"
                },
                {
                    "first": "Olumuyiwa O.",
                    "initial": "O.O.",
                    "last": "Odusanya"
                },
                {
                    "first": "Abdoulbaki I.",
                    "initial": "A.I.",
                    "last": "Diallo"
                },
                {
                    "first": "Gaoussou",
                    "initial": "G.",
                    "last": "Santara"
                },
                {
                    "first": "Amadou",
                    "initial": "A.",
                    "last": "Barry"
                },
                {
                    "first": "Amagana",
                    "initial": "A.",
                    "last": "Dolo"
                },
                {
                    "first": "Aminata",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Yetunde A.",
                    "initial": "Y.A.",
                    "last": "Kuyinu"
                },
                {
                    "first": "Omolara A.",
                    "initial": "O.A.",
                    "last": "Kehinde"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Fran\u00e7ois"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Juan P.",
                    "initial": "J.P.",
                    "last": "Yarzabal"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1186/1471-2458-11-882",
            "issn": "14712458",
            "pmid": "22112189",
            "pub_year": 2011,
            "title": "Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: A randomized controlled trial",
            "volume": "11"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Sodiomon B.",
                    "initial": "S.B.",
                    "last": "Sirima"
                },
                {
                    "first": "Alfred",
                    "initial": "A.",
                    "last": "Tiono"
                },
                {
                    "first": "Zakaria",
                    "initial": "Z.",
                    "last": "Gansan\u00e9"
                },
                {
                    "first": "Mohamadou",
                    "initial": "M.",
                    "last": "Siribi\u00e9"
                },
                {
                    "first": "Ang\u00e8le",
                    "initial": "A.",
                    "last": "Zongo"
                },
                {
                    "first": "Alphonse",
                    "initial": "A.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Fran\u00e7ois"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Strezova"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1097/INF.0000000000001518",
            "firstpage": "e136",
            "issn": "08913668",
            "lastpage": "e150",
            "pmid": "28403055",
            "pub_year": 2016,
            "title": "Immunogenicity and safety of 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered to children with sickle cell disease between 8 weeks and 2 years of age: A phase III, open, controlled study",
            "volume": "36"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Czajka"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Ars\u00e8ne"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f8ef",
            "firstpage": "S66",
            "issn": "08913668",
            "lastpage": "S76",
            "pmid": "19325449",
            "pub_year": 2009,
            "title": "Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine",
            "volume": "28"
        },
        "b0140": null
    },
    "body_text": [
        {
            "endOffset": 37514,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Co-administered vaccines were managed through sequential numbering of treatment and were administered by the site staff.",
            "startOffset": 37394,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 50870,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Observed OPA GMTs were higher in the PCV13 group and decreased post-primary vaccination (Fig. 3 and Table S2).",
            "startOffset": 50760,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 34958,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, it was important to assess whether addition of these pneumococcal proteins alter the immune response to the PHiD-CV serotype-specific PS conjugates or to the co-administered routine paediatric vaccines.",
            "startOffset": 34745,
            "title": "Introduction"
        },
        {
            "endOffset": 56408,
            "parents": [],
            "secId": "s0085",
            "sentence": "These results were similar to our study where low percentages of infants with injection site swelling and redness were reported.",
            "startOffset": 56280,
            "title": "Discussion"
        },
        {
            "endOffset": 37985,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 37984,
                    "startOffset": 37980
                }
            },
            "secId": "s0025",
            "sentence": "PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 contained the 10 PHiD-CV PS conjugates combined with either 10 or 30 \u00b5g of dPly and PhtD each, as detailed previously [17].",
            "startOffset": 37816,
            "title": "Study vaccines"
        },
        {
            "endOffset": 55374,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 55264,
                    "startOffset": 55260
                }
            },
            "secId": "s0085",
            "sentence": "Pain was the most commonly reported injection site symptom for co-administered vaccines, in line with results described by Dicko et al. [25] in children in the same age group in African settings who received PHiD-CV co-administered with DTPw-HBV/Hib.",
            "startOffset": 55124,
            "title": "Discussion"
        },
        {
            "endOffset": 61864,
            "parents": [],
            "secId": "s0105",
            "sentence": "EOO also participated in the training of some of the staff on study procedures.",
            "startOffset": 61785,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 62154,
            "parents": [],
            "secId": "s0105",
            "sentence": "AW was involved in centre coordination, data collection, and quality checks.",
            "startOffset": 62078,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 59915,
            "parents": [],
            "secId": "s0090",
            "sentence": "The study was funded by PATH, Seattle, USA, and GlaxoSmithKline Biologicals SA, Belgium.",
            "startOffset": 59827,
            "title": "Funding"
        },
        {
            "endOffset": 55932,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 55931,
                    "startOffset": 55927
                }
            },
            "secId": "s0085",
            "sentence": "Reactogenicity data were collected by field workers in our study, but by either field workers (in Nigeria) or study physicians (in Mali) in the study by Dicko et al [25].",
            "startOffset": 55762,
            "title": "Discussion"
        },
        {
            "endOffset": 39808,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Pneumococcal vaccines were administered at either 2, 3, and 4 months of age (3+0 schedule) or 2, 4, and 9 months of age (2+1 schedule).",
            "startOffset": 39673,
            "title": "Study vaccines"
        },
        {
            "endOffset": 41305,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immune responses to pneumococcal vaccines were evaluated pre-vaccination, and 1, 5, and 8 months post-dose 3 for the 3+0 schedule; or pre-vaccination, 1 and 5 months post-dose 2, and 3 months post-dose 3 for the 2+1 schedule.",
            "startOffset": 41080,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 57691,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 57690,
                    "startOffset": 57686
                }
            },
            "secId": "s0085",
            "sentence": "In the non-inferiority study for PHiD-CV licensure, non-inferiority of PHiD-CV compared to PCV7 could not be shown for serotypes 6B and 23F at 1 month post-primary vaccination [27].",
            "startOffset": 57510,
            "title": "Discussion"
        },
        {
            "endOffset": 36041,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase II, randomised, controlled, observer-blind, single centre study (NCT01262872) conducted in The Gambia between June 2011 and March 2013.",
            "startOffset": 35889,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40748,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The results of these objectives are disclosed here.",
            "startOffset": 40697,
            "title": "Study objectives"
        },
        {
            "endOffset": 37799,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The study was conducted in an observer-blind manner within each defined pneumococcal vaccination schedule, meaning that vaccine recipients, sponsor, laboratory personnel and anyone responsible for evaluation of any study endpoint were unaware of the administered pneumococcal vaccine.",
            "startOffset": 37515,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 56543,
            "parents": [],
            "secId": "s0085",
            "sentence": "As this study used both PHiD-CV and PCV13 as controls, it provided a unique opportunity to assess their immunogenicity in this setting.",
            "startOffset": 56408,
            "title": "Discussion"
        },
        {
            "endOffset": 34577,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 34576,
                    "startOffset": 34569
                },
                "b0060": {
                    "endOffset": 34576,
                    "startOffset": 34569
                },
                "b0065": {
                    "endOffset": 34576,
                    "startOffset": 34569
                }
            },
            "secId": "s0005",
            "sentence": "These new protein antigens were combined with a PCV into one vaccine: the protein-based pneumococcal vaccine containing 10 serotype-specific PS conjugates of the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) combined with dPly and PhtD (PHiD-CV/dPly/PhtD) [11\u201313].",
            "startOffset": 34272,
            "title": "Introduction"
        },
        {
            "endOffset": 33674,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 33673,
                    "startOffset": 33668
                },
                "b0015": {
                    "endOffset": 33673,
                    "startOffset": 33668
                }
            },
            "secId": "s0005",
            "sentence": "While Streptococcus pneumoniae has more than 90 serotypes, only 6\u201311 of these serotypes were responsible for \u226570% of all invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) [2,3].",
            "startOffset": 33436,
            "title": "Introduction"
        },
        {
            "endOffset": 37068,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In the remaining participants (100 per group), serological testing of co-administered vaccine antigens (co-ad subset) was performed.",
            "startOffset": 36936,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 44706,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Statistical analyses were performed using Statistical Analysis System Discovery Drug on Windows.",
            "startOffset": 44610,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42333,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For 19A, a serotype-specific cut-off was applied, corresponding to the lower limit of quantitation determined for this serotype in the multiplex assay (opsonic titre of 143).",
            "startOffset": 42159,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 50083,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "For the PCV13 group this percentage was 99.0% for serotypes 3 and 6A, and 100% for 19A (Table 2).",
            "startOffset": 49986,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 52153,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "At least 98.0% of children in each group were considered seroprotected against pertussis, and \u226596.6% were considered seroprotected against hepatitis B (Table 4).",
            "startOffset": 51992,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 36816,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Infants were randomised 1:1:1:1:1:1 into 6 parallel groups to receive PHiD-CV/dPly/PhtD-30, PHiD-CV/dPly/PhtD-10, PHiD-CV (Synflorix; GSK), or 13-valent PCV (PCV13; Prevenar 13; Pfizer) according to a 3+0 schedule, or PHiD-CV/dPly/PhtD-30 or PHiD-CV in a 2+1 schedule (Fig. 1).",
            "startOffset": 36539,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 53034,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 53033,
                    "startOffset": 53029
                }
            },
            "secId": "s0080",
            "sentence": "General symptoms, local reactogenicity at the injection site of the pneumococcal vaccines, incidence of unsolicited adverse events after priming and booster vaccine doses, and incidence of serious adverse events were reported previously [16].",
            "startOffset": 52792,
            "title": "Reactogenicity of co-administered vaccines"
        },
        {
            "endOffset": 46211,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Antibody concentrations and titres below assay cut-offs were given an arbitrary value of half the cut-off for GMC and GMT calculations.",
            "startOffset": 46076,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42020,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 41928,
                    "startOffset": 41924
                }
            },
            "secId": "s0035",
            "sentence": "Pneumococcal serotype-specific OPA was measured at the above-mentioned time points except pre-vaccination, by a killing-assay using an HL60 cell line [19], in single-plex for all serotypes except serotype 19A for which a multiplex assay was used.",
            "startOffset": 41774,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 50564,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In PHiD-CV groups for both schedules, observed antibody GMCs for these 3 serotypes decreased post-primary vaccination, and remained below pre-vaccination levels except for 2+1 groups where an increase in antibody GMCs was observed for serotype 19A post-booster vaccination (Fig. 2 and Table S1).",
            "startOffset": 50269,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 48691,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Increases in antibody GMCs were observed post-booster vaccination for PHiD-CV/dPly/PhtD-30 and PHiD-CV administered as a 2+1 schedule.",
            "startOffset": 48557,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 46659,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 46658,
                    "startOffset": 46654
                }
            },
            "secId": "s0055",
            "sentence": "Demographic characteristics were similar across groups and have been previously published [16].",
            "startOffset": 46564,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 49706,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "One month post-primary vaccination, the percentage of infants with antibody concentrations \u22650.2 \u00b5g/mL ranged from 6.3% to 10.3% for serotype 3, from 21.9% to 34.6% for serotype 6A and from 47.9% to 56.5% for serotype 19A across all groups except for the PCV13 group, where all infants had antibody concentrations \u22650.2 \u00b5g/mL for serotype 3, and 99.5% and 98.4% for serotype 6A and 19A, respectively (Table 1).",
            "startOffset": 49298,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 52321,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "For all groups, the percentages of children considered seroprotected against poliovirus 1, 2, and 3 were 89.1\u201396.8%, 93.4\u2013100%, and 85.3\u201395.5%, respectively (Table 4).",
            "startOffset": 52154,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 45237,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Total vaccinated cohort (TVC) for safety included all participants with at least 1 study vaccine administration documented.",
            "startOffset": 45114,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 49886,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the 3+0 and 2+1 schedules, the percentage of infants in the PHiD-CV groups having OPA titres \u22658 ranged from 5.4% to 8.7% for serotype 3 and from 13.4% to 29.5% for serotype 6A.",
            "startOffset": 49707,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 43462,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 43461,
                    "startOffset": 43457
                }
            },
            "secId": "s0035",
            "sentence": "Antibody titres \u22658 for poliovirus types 1, 2, and 3 determined by a virus micro-neutralisation test adapted from WHO guidelines were considered as seropositive and protective [20].",
            "startOffset": 43282,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 46563,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "All infants were African.",
            "startOffset": 46538,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 49124,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For the majority of the 10 common vaccine pneumococcal serotypes, OPA responses were within similar ranges across all groups at 1 and 5 months post-primary vaccination.",
            "startOffset": 48956,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 61541,
            "parents": [],
            "secId": "s0105",
            "sentence": "MOCO was involved in planning, data collection, review, project oversight on site and was involved in the conception of the study design, trained and supervised clinicians and staff on study procedures, clinically evaluated and investigated the patients, maintained quality assurance over clinical procedures, and supervised the laboratory work.",
            "startOffset": 61196,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 62077,
            "parents": [],
            "secId": "s0105",
            "sentence": "PKO supervised the laboratory work.",
            "startOffset": 62042,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 63574,
            "parents": [],
            "secId": "s0105",
            "sentence": "All authors had full access to all data in the study, contributed to the writing of this report, and had final responsibility for the decision to submit for publication.",
            "startOffset": 63405,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 58389,
            "parents": [],
            "secId": "s0085",
            "sentence": "A limitation of this study is the fact that the assessment of immune responses for the PS conjugates and the co-administered vaccines was descriptive, which was justified by the phase II design of the study.",
            "startOffset": 58182,
            "title": "Discussion"
        },
        {
            "endOffset": 45561,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "According-to-protocol (ATP) cohort for immunogenicity analysis included all evaluable participants (i.e. those meeting all eligibility criteria, complying with protocol-defined procedures and intervals, with no elimination criteria during the study) for whom data concerning immunogenicity endpoint measures were available.",
            "startOffset": 45238,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 54084,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 54083,
                    "startOffset": 54079
                },
                "b0065": {
                    "endOffset": 54065,
                    "startOffset": 54061
                }
            },
            "secId": "s0085",
            "sentence": "These results are in line with previous findings from European studies assessing pneumococcal protein-containing formulations in infants [13] and toddlers [12].",
            "startOffset": 53924,
            "title": "Discussion"
        },
        {
            "endOffset": 54523,
            "parents": [],
            "secId": "s0085",
            "sentence": "Based on the observed immune responses to PHiD-CV in the current study, showing no substantial difference when combined in PHiD-CV/dPly/PhtD formulations, we can presume that the vaccine efficacy of the PS conjugates against pneumococcal disease would remain unaffected when combined with dPly and PhtD.",
            "startOffset": 54220,
            "title": "Discussion"
        },
        {
            "endOffset": 36172,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 36171,
                    "startOffset": 36167
                }
            },
            "secId": "s0015",
            "sentence": "Inclusion and exclusion criteria were presented previously [16].",
            "startOffset": 36108,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42158,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For all serotypes but 19A, a generic cut-off was applied (opsonic titre of 8), corresponding to the lowest sample dilution in the assays.",
            "startOffset": 42021,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 45850,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Maximum interval allowed between primary vaccine doses was 28\u201348 days for 3+0 schedule and 49\u201390 days for 2+1 schedule; booster dose was administered at approximately 9\u201310 months of age.",
            "startOffset": 45664,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 63117,
            "parents": [],
            "secId": "s0105",
            "sentence": "KD was involved in interpretation of the results, coordination, and reporting of the study.",
            "startOffset": 63026,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 48955,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For all PHiD-CV serotypes, observed antibody GMCs at 12 months of age were higher in the 2+1 compared to 3+0 groups in the PHiD-CV-vaccinated groups (i.e. 3 months post-booster for 2+1 or 8 months post-primary vaccination for 3+0 schedules) (Fig. 2 and Table S1).",
            "startOffset": 48692,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 53255,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "For all co-administered vaccine doses, whatever the pneumococcal vaccine and vaccination schedule, injection site pain was the most frequent solicited local symptom both post-primary and post-booster vaccination (Fig. 4).",
            "startOffset": 53034,
            "title": "Reactogenicity of co-administered vaccines"
        },
        {
            "endOffset": 55761,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 55649,
                    "startOffset": 55645
                }
            },
            "secId": "s0085",
            "sentence": "This disparity could be due to the different DTPw-HBV/Hib vaccines that were administered (Zilbrix in the previous study [25], Tritanrix-HepB/Hib in this study), or to differences in the method used in the reactogenicity data collection.",
            "startOffset": 55524,
            "title": "Discussion"
        },
        {
            "endOffset": 38548,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "PCV13 contained 2 \u00b5g of each pneumococcal PS for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 4 \u00b5g for serotype 6B conjugated to cross-reactive material CRM197 carrier protein.",
            "startOffset": 38352,
            "title": "Study vaccines"
        },
        {
            "endOffset": 50268,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the PCV13 group, observed antibody GMCs for serotypes 3, 6A and 19A increased post-primary vaccination but waned in the following months while remaining above pre-vaccination levels.",
            "startOffset": 50083,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 33900,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 33899,
                    "startOffset": 33894
                },
                "b0025": {
                    "endOffset": 33899,
                    "startOffset": 33894
                },
                "b0030": {
                    "endOffset": 33899,
                    "startOffset": 33894
                }
            },
            "secId": "s0005",
            "sentence": "From the year 2000 onwards, PCVs containing capsular polysaccharides (PSs) of the most prevalent IPD-causing serotypes conjugated to a carrier protein have been successfully used in preventing IPD in children worldwide [4\u20136].",
            "startOffset": 33675,
            "title": "Introduction"
        },
        {
            "endOffset": 42771,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Diphtheria and tetanus antibody concentrations were measured using standard in-house ELISA; an antibody concentration of \u22650.1 IU/mL was defined as the cut-off for seroprotection.",
            "startOffset": 42593,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 43073,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibodies against recombinant hepatitis B surface antigen were measured by an in-house chemiluminescent immunoassay (cut-off: 6.2 mIU/mL).",
            "startOffset": 42934,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 60821,
            "parents": [],
            "secId": "s0100",
            "sentence": "Stamaril is a trademark of Sanofi Pasteur.",
            "startOffset": 60779,
            "title": "Trademark statement"
        },
        {
            "endOffset": 41080,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Blood samples were collected from each participant at 2, 5, 9, and 12 months of age (Fig. 1).",
            "startOffset": 40987,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 37393,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Treatment numbers were allocated by dose.",
            "startOffset": 37352,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 40959,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The impact of dPly and PhtD in the PHiD-CV/dPly/PhtD investigational formulations on the nasopharyngeal carriage of bacteria other than Streptococcus pneumoniae can be found at ClinicalTrials.gov (NCT01262872).",
            "startOffset": 40749,
            "title": "Study objectives"
        },
        {
            "endOffset": 50759,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "For serotypes 3, 6A and 19A, at each timepoint, OPA responses were within similar ranges across all PHiD-CV groups except an increase in 19A OPA titre post-booster vaccination in the 2+1 groups.",
            "startOffset": 50565,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 34744,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 34743,
                    "startOffset": 34736
                },
                "b0075": {
                    "endOffset": 34743,
                    "startOffset": 34736
                }
            },
            "secId": "s0005",
            "sentence": "Infant vaccination programmes are becoming increasingly elaborate through the addition of new vaccines that are co-administered to reduce the number of visits [14,15].",
            "startOffset": 34577,
            "title": "Introduction"
        },
        {
            "endOffset": 39032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "One dose of diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b vaccine (DTPw-HBV/Hib, Tritanrix-HepB/Hib, GSK) (0.5 mL) contained \u226530 International Units (IU) of diphtheria toxoid, \u226560 IU of tetanus toxoid, \u22654 IU of killed Bordetella pertussis, 10 \u00b5g of recombinant hepatitis B surface antigen and a pellet containing 10 \u00b5g of polyribosyl-ribitol-phosphate (PRP) conjugated to 20\u201340 \u00b5g of tetanus toxoid to be reconstituted with the DTPw-HBV suspension.",
            "startOffset": 38548,
            "title": "Study vaccines"
        },
        {
            "endOffset": 62699,
            "parents": [],
            "secId": "s0105",
            "sentence": "MAl was involved in planning, designing, and reviewing the reported study and interpretation of the results.",
            "startOffset": 62591,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 46476,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Out of 1200 infants in the TVC, 1164 were included in the ATP cohort for immunogenicity and 1152 completed the study.",
            "startOffset": 46359,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 35155,
            "parents": [],
            "secId": "s0005",
            "sentence": "This phase II study in Gambian children assessed the efficacy of two formulations of the PHiD-CV/dPly/PhtD vaccine against pneumococcal nasopharyngeal carriage, and their immunogenicity and safety.",
            "startOffset": 34958,
            "title": "Introduction"
        },
        {
            "endOffset": 43824,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody titres \u226510 were considered seroprotective.",
            "startOffset": 43773,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 62345,
            "parents": [],
            "secId": "s0105",
            "sentence": "OTI and OO were involved in clinical evaluation and investigation of the study participants, trained study team staff on procedures and maintained quality assurance over clinical procedures.",
            "startOffset": 62155,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 62041,
            "parents": [],
            "secId": "s0105",
            "sentence": "YS trained and supervised clinicians and staff on study procedures and clinically evaluated and investigated patients and maintained quality assurance over clinical procedures.",
            "startOffset": 61865,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 35849,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we report on the immune response to the serotype-specific PS conjugates, as well as immunogenicity and reactogenicity of co-administered Expanded Programme on Immunisation (EPI) vaccines.",
            "startOffset": 35656,
            "title": "Introduction"
        },
        {
            "endOffset": 40262,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Study staff administered pneumococcal vaccines intramuscularly into the right thigh, and co-administered injectable vaccines (DTPw-HBV/Hib, measles, yellow fever) intramuscularly into the left thigh.",
            "startOffset": 40063,
            "title": "Study vaccines"
        },
        {
            "endOffset": 61784,
            "parents": [],
            "secId": "s0105",
            "sentence": "EOO clinically evaluated and investigated the patients and maintained quality assurance over clinical procedures.",
            "startOffset": 61671,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 63405,
            "parents": [],
            "secId": "s0105",
            "sentence": "DB was involved in planning, designing, and reviewing the reported study, analysis plan, interpretation of the results, safety (interaction with and reporting to the Data and Safety Monitoring Board/Independent Data Monitoring Committee), project oversight, and writing the final report.",
            "startOffset": 63118,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 42430,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Protein D antibodies were quantified using an ELISA with a cut-off of 100 ELISA units (EL.U)/mL.",
            "startOffset": 42334,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 52747,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "In both schedules, immune responses to the co-administered vaccines were similar between PHiD-CV/dPly/PhtD and PHiD-CV groups.",
            "startOffset": 52621,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 40062,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "All participants received DTPw-HBV/Hib and OPV at 2, 3, and 4 months of age, and measles, yellow fever, and OPV vaccines at 9 months of age (the 4th dose of OPV was added to study procedures to comply with national immunisation programme in The Gambia).",
            "startOffset": 39809,
            "title": "Study vaccines"
        },
        {
            "endOffset": 57898,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 57790,
                    "startOffset": 57783
                },
                "b0110": {
                    "endOffset": 57790,
                    "startOffset": 57783
                },
                "b0115": {
                    "endOffset": 57790,
                    "startOffset": 57783
                },
                "b0120": {
                    "endOffset": 57790,
                    "startOffset": 57783
                },
                "b0140": {
                    "endOffset": 57897,
                    "startOffset": 57893
                }
            },
            "secId": "s0085",
            "sentence": "However, several trials and post-marketing studies have reported efficacy data for PHiD-CV [21\u201324], and efficacy/effectiveness of both PHiD-CV and PCV13 is further exemplified by a recent review paper [28].",
            "startOffset": 57692,
            "title": "Discussion"
        },
        {
            "endOffset": 35655,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 35654,
                    "startOffset": 35650
                }
            },
            "secId": "s0005",
            "sentence": "Both formulations elicited immune responses to the pneumococcal proteins in infants [16].",
            "startOffset": 35566,
            "title": "Introduction"
        },
        {
            "endOffset": 36338,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 36337,
                    "startOffset": 36333
                }
            },
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each parent/legally acceptable representative before vaccination, except for a few deviations as previously presented [16].",
            "startOffset": 36172,
            "title": "Study design and participants"
        },
        {
            "endOffset": 61195,
            "parents": [],
            "secId": "s0105",
            "sentence": "AO was involved in planning, data collection, site coordination of study, review of the reported study, and trained and supervised clinicians and staff on study procedures, clinically evaluated and investigated the patients, maintained quality assurance over clinical procedures, and drafted the report.",
            "startOffset": 60892,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 45663,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "These included children with results for at least 1 study vaccine antigen component post-vaccination.",
            "startOffset": 45562,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 60472,
            "parents": [],
            "secId": "s0095",
            "sentence": "A protocol summary and the results summary for this study (GSK study number 114174 \u2013 NCT01262872) are available on the GSK Clinical Study Register and can be accessed at https://www.gsk-studyregister.com.",
            "startOffset": 60268,
            "title": "Data sharing statement"
        },
        {
            "endOffset": 33435,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 33434,
                    "startOffset": 33431
                }
            },
            "secId": "s0005",
            "sentence": "Pneumococcal disease mainly affects infants and young children and is responsible for approximately 500,000 deaths of children under 5 years of age every year [1].",
            "startOffset": 33272,
            "title": "Introduction"
        },
        {
            "endOffset": 39673,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Yellow fever vaccine (Stamaril, Sanofi Pasteur) (0.5 mL) contained a freeze-dried pellet of live attenuated yellow fever virus (17 D-204 strain) \u22651000 IU.",
            "startOffset": 39519,
            "title": "Study vaccines"
        },
        {
            "endOffset": 49252,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Increases in OPA GMTs were observed following booster vaccination in the 2+1 schedule for most serotypes (Fig. 3 and Table S2).",
            "startOffset": 49125,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 47818,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within the 3+0 schedule, for serotypes 6B and 23F, the percentage of infants with antibody concentrations above the cut-off appeared to be lower in the PHiD-CV group compared to the PCV13 group at 1 month post-primary vaccination; however at 5 and 8 months post-primary vaccination, those percentages for serotypes 6B and 23F appeared lower in the PCV13 group compared to the PHiD-CV group (Table 1).",
            "startOffset": 47418,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 61670,
            "parents": [],
            "secId": "s0105",
            "sentence": "MAn was involved in planning, designing, and reviewing the reported study, the analysis plan, and interpretation of the results.",
            "startOffset": 61542,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 62590,
            "parents": [],
            "secId": "s0105",
            "sentence": "BMG contributed to the study design, development of the study protocol, analysis plan, interpretation of the results, and writing the final report.",
            "startOffset": 62443,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 58705,
            "parents": [],
            "secId": "s0085",
            "sentence": "Another limitation is the fact that polio vaccination campaigns were run in The Gambia in 2011 and 2012.",
            "startOffset": 58601,
            "title": "Discussion"
        },
        {
            "endOffset": 54918,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 54917,
                    "startOffset": 54913
                }
            },
            "secId": "s0085",
            "sentence": "Similarly, in a study in European children, the immune response induced by DTPa-HBV-IPV/Hib vaccine did not appear altered when co-administered at 2, 3, 4, and 12\u201315 months of age with PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30 formulations [13].",
            "startOffset": 54670,
            "title": "Discussion"
        },
        {
            "endOffset": 44200,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Intensity for the local adverse events (AEs) was assessed with grades from 1 to 3; grade 3 for pain was considered crying when limb was moved or limb was spontaneously painful, and for swelling and redness, >30 mm surface diameter.",
            "startOffset": 43969,
            "title": "Reactogenicity assessment"
        },
        {
            "endOffset": 58600,
            "parents": [],
            "secId": "s0085",
            "sentence": "Also, due to the non-standard interval used for post-booster timepoint (3 months from last dose), no direct comparison between post-primary (1 month from last dose) and post-booster vaccinations should be made.",
            "startOffset": 58390,
            "title": "Discussion"
        },
        {
            "endOffset": 63025,
            "parents": [],
            "secId": "s0105",
            "sentence": "VV contributed to study design, review of the analysis plan, interpretation of the results, and laboratory work supervision.",
            "startOffset": 62901,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 51480,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Eight months post-primary vaccination, the percentage of children with anti-protein D concentrations \u2265100 EL.U/mL had decreased in 3+0 groups, while an increase was reported post-booster for 2+1 groups (Table 3).",
            "startOffset": 51268,
            "title": "Immune response against protein D"
        },
        {
            "endOffset": 43130,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Concentrations of \u226510 mIU/mL were considered protective.",
            "startOffset": 43074,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 57509,
            "parents": [],
            "secId": "s0085",
            "sentence": "For serotypes 6B and 23F, at 1 month post-primary vaccination, immune responses appeared to be lower in the PHiD-CV group compared to the PCV13 group; however, this trend reversed at later time points, suggesting a difference in antibody kinetics and persistence for these serotypes elicited by the two vaccines.",
            "startOffset": 57197,
            "title": "Discussion"
        },
        {
            "endOffset": 55123,
            "parents": [],
            "secId": "s0085",
            "sentence": "No apparent differences in reactogenicity were observed when co-administering DTPw-HBV/Hib, measles and yellow fever vaccines with PHiD-CV/dPly/PhtD formulations compared to co-administration with PHiD-CV.",
            "startOffset": 54918,
            "title": "Discussion"
        },
        {
            "endOffset": 43772,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibodies against yellow fever virus were determined by a plaque reduction neutralisation test by Focus Diagnostics Inc, California, US.",
            "startOffset": 43635,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 53453,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most frequent grade 3 injection site symptom was swelling, reported in up to 4% of infants in the PHiD-CV/dPly/PhtD-30 (2+1) group following the first dose of the DTPw-HBV/Hib vaccine (Fig. 4).",
            "startOffset": 53256,
            "title": "Reactogenicity of co-administered vaccines"
        },
        {
            "endOffset": 55523,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 55487,
                    "startOffset": 55483
                }
            },
            "secId": "s0085",
            "sentence": "Incidences of pain and swelling at the DTPw-HBV/Hib injection site were higher in the study of Dicko et al. [25] than observed in the current study.",
            "startOffset": 55375,
            "title": "Discussion"
        },
        {
            "endOffset": 53923,
            "parents": [],
            "secId": "s0085",
            "sentence": "Both PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 induced immune responses against each of the PHiD-CV vaccine serotypes and against protein D, in similar ranges as observed in PHiD-CV vaccinees.",
            "startOffset": 53727,
            "title": "Discussion"
        },
        {
            "endOffset": 62810,
            "parents": [],
            "secId": "s0105",
            "sentence": "MT was involved in planning, designing, and reviewing the reported study and statistical analysis of the data.",
            "startOffset": 62700,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 60870,
            "parents": [],
            "secId": "s0100",
            "sentence": "M-Vac is a trademark of Serum Institute of India.",
            "startOffset": 60821,
            "title": "Trademark statement"
        },
        {
            "endOffset": 47417,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month post-primary vaccination, for each of the 10 PHiD-CV serotypes common to the pneumococcal study vaccines, \u226597.4% of children in the groups who received a 3+0 schedule and \u226596.4% of children in the groups with a 2+1 schedule had antibody concentrations \u22650.2 \u03bcg/mL, except for serotypes 6B (78.4\u201392.7% [3+0] and 72.0\u201372.5% [2+1]) and 23F (86.8\u201397.4% [3+0] and 76.2\u201377.8% [2+1]) (Table 1).",
            "startOffset": 47021,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 63962,
            "parents": [],
            "secId": "s0110",
            "sentence": "MT is employed by the GSK group of companies.",
            "startOffset": 63917,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 39518,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Measles vaccine (M-Vac, Serum Institute of India) (0.5 mL) contained a freeze-dried pellet of live attenuated measles virus (Edmonston Zagreb strain) \u22651000 50% cell culture infectious dose.",
            "startOffset": 39329,
            "title": "Study vaccines"
        },
        {
            "endOffset": 43634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Measles antibodies were titrated using commercially available Enzygnost ELISA kits manufactured by Dade Behring (assay cut-off and cut-off for seroprotection: 150 mIU/mL).",
            "startOffset": 43463,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 46075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Geometric mean antibody concentrations (GMCs) and geometric mean titres (GMTs) were calculated with 95% confidence intervals (CIs) by taking the anti-log of the mean of the log antibody concentration or titre transformations.",
            "startOffset": 45850,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35565,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 35526,
                    "startOffset": 35522
                },
                "b0085": {
                    "endOffset": 35564,
                    "startOffset": 35560
                }
            },
            "secId": "s0005",
            "sentence": "We previously reported that inclusion of dPly and PhtD in the PHiD-CV/dPly/PhtD investigational formulations had no impact on pneumococcal nasopharyngeal carriage prevalence beyond the protection already provided by the licensed PHiD-CV, regardless of protein dose or schedule; and that the PHiD-CV/dPly/PhtD formulations had an acceptable safety profile in infants [16] and in children 2\u20134 years of age [17].",
            "startOffset": 35156,
            "title": "Introduction"
        },
        {
            "endOffset": 60727,
            "parents": [],
            "secId": "s0100",
            "sentence": "Synflorix, Tritanrix, Zilbrix and Polio Sabin are trademarks licensed to the GSK group of companies.",
            "startOffset": 60627,
            "title": "Trademark statement"
        },
        {
            "endOffset": 62442,
            "parents": [],
            "secId": "s0105",
            "sentence": "BK was involved in project oversight, laboratory work supervision and interpretation of results.",
            "startOffset": 62346,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 57196,
            "parents": [],
            "secId": "s0085",
            "sentence": "Immune responses for serotypes 18C and 19F tended to be higher for the PHiD-CV group compared with the PCV13 group while immune responses for serotypes 1, 5, and 14 appeared higher for the PCV13 group.",
            "startOffset": 56995,
            "title": "Discussion"
        },
        {
            "endOffset": 51267,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-primary vaccination, in groups receiving the 3+0 schedule, all participants in the PHiD-CV/dPly/PhtD-30, PHiD-CV/dPly/PhtD-10, or PHiD-CV groups and 39.7% of infants in the PCV13 group had anti-protein D concentrations \u2265100 EL.U/mL (Table 3), compared to 98.9% and 100% of participants receiving PHiD-CV/dPly/PhtD-30 or PHiD-CV in a 2+1 schedule.",
            "startOffset": 50906,
            "title": "Immune response against protein D"
        },
        {
            "endOffset": 64383,
            "parents": [],
            "secId": "s0110",
            "sentence": "The GSK group of companies, MRC, and LSHTM employees report a grant from PATH to their institutions for the conduct of this study.",
            "startOffset": 64253,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 48070,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month post-primary vaccination, for each of the 10 PHiD-CV serotypes, the percentage of children with OPA titres \u22658 was \u226585.3% in the 3+0 groups and \u226582.5% in the 2+1 groups, except for serotype 1 (74.0\u201390.3% [3+0] and 75.3\u201375.5% [2+1]) (Table 2).",
            "startOffset": 47819,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 58182,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 58181,
                    "startOffset": 58178
                }
            },
            "secId": "s0085",
            "sentence": "A systematic review of literature on the impact or effectiveness of PHiD-CV and PCV13 on deaths or hospitalisation due to IPD, pneumonia, meningitis, and sepsis in children below 5 years of age, also showed that there was no evidence of superiority of one vaccine over the other [6].",
            "startOffset": 57899,
            "title": "Discussion"
        },
        {
            "endOffset": 48556,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within the 3+0 schedule, antibody levels post-primary vaccination appeared lower for serotypes 18C and 19F in the PCV13 group compared with PHiD-CV recipients, while the opposite was observed for serotypes 1, 5, and 14 (Fig. 2 and Table S1).",
            "startOffset": 48315,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 64072,
            "parents": [],
            "secId": "s0110",
            "sentence": "MOCO, KS, VV, and DB are employed by the GSK group of companies and own shares of the GSK group of companies.",
            "startOffset": 63963,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 54669,
            "parents": [],
            "secId": "s0085",
            "sentence": "Pneumococcal protein antigens seemed not to alter immune responses to co-administered EPI vaccines (DTPw-HBV/Hib, OPV, measles, and yellow fever).",
            "startOffset": 54523,
            "title": "Discussion"
        },
        {
            "endOffset": 44357,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Each parent(s)/legally acceptable representative(s) was instructed to contact the investigator immediately should the infant manifest any signs or symptoms.",
            "startOffset": 44201,
            "title": "Reactogenicity assessment"
        },
        {
            "endOffset": 39328,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "One dose of oral trivalent polio vaccine (OPV, Polio Sabin, GSK) (0.135 mL) contained a solution with poliovirus type 1 (LS-c, 2ab strain) 106 50% tissue culture infectious dose (TCID50), poliovirus type 2 (P712, Ch, 2ab strain) 105 TCID50 and poliovirus type 3 (Leon 12a1b strain) 105.8 TCID50.",
            "startOffset": 39033,
            "title": "Study vaccines"
        },
        {
            "endOffset": 58854,
            "parents": [],
            "secId": "s0085",
            "sentence": "Some of the children may have received additional doses of polio vaccine; these children were not eliminated from the ATP cohort for immunogenicity.",
            "startOffset": 58706,
            "title": "Discussion"
        },
        {
            "endOffset": 36510,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with principles of Good Clinical Practice and the Declaration of Helsinki, and is registered at www.clinicaltrials.gov (NCT01262872).",
            "startOffset": 36339,
            "title": "Study design and participants"
        },
        {
            "endOffset": 63770,
            "parents": [],
            "secId": "s0110",
            "sentence": "AO received support for study-related travel to conferences from the GSK group of companies.",
            "startOffset": 63678,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 51890,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "One month post-vaccination, all children in all groups had antibody levels equal to or above the seroprotective threshold for diphtheria, tetanus, and Hib.",
            "startOffset": 51735,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 56994,
            "parents": [],
            "secId": "s0085",
            "sentence": "For the majority of the common serotypes, no major differences were observed between PHiD-CV and PCV13.",
            "startOffset": 56891,
            "title": "Discussion"
        },
        {
            "endOffset": 63851,
            "parents": [],
            "secId": "s0110",
            "sentence": "BK\u2019s institution received grant from Pfizer and PATH outside the submitted work.",
            "startOffset": 63771,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 38351,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Its protein carrier content is 9\u201316 \u00b5g of protein D, 3\u20136 \u00b5g of diphtheria toxoid, and 5\u201310 \u00b5g of tetanus toxoid.",
            "startOffset": 38239,
            "title": "Study vaccines"
        },
        {
            "endOffset": 49985,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In both schedules, the percentage of infants having 19A OPA titre \u2265143 ranged from 35.2% to 59.2%.",
            "startOffset": 49887,
            "title": "Immune response to serotypes 3, 6A, and 19A"
        },
        {
            "endOffset": 59994,
            "parents": [],
            "secId": "s0090",
            "sentence": "PATH was involved in the study design, data analysis, and data interpretation.",
            "startOffset": 59916,
            "title": "Funding"
        },
        {
            "endOffset": 46321,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Seropositivity/seroprotection rates with exact 95% CIs were calculated for each appropriate serotype/antigen.",
            "startOffset": 46212,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 59563,
            "parents": [],
            "secId": "s0085",
            "sentence": "To conclude, both pneumococcal vaccine formulations containing the proteins dPly and PhtD induced similar immune responses against the 10 common vaccine serotypes and protein D at all post-vaccination time points as observed for PHiD-CV.",
            "startOffset": 59326,
            "title": "Discussion"
        },
        {
            "endOffset": 47021,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within the same vaccination schedule, the infants\u2019 immune responses were similar for the PHiD-CV/dPly/PhtD and PHiD-CV groups in terms of antibody GMCs, OPA GMTs, and proportion of infants with antibody levels and OPA titres above the cut-off values (Tables 1 and 2; Figs. 2 and 3; Tables S1 and S2).",
            "startOffset": 46721,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 48314,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In both schedules, for all 10 common serotypes, antibody GMCs increased post-primary vaccination but waned in the following months, while remaining above pre-vaccination levels (except for serotype 14 in the 2+1 groups pre-booster vaccination).",
            "startOffset": 48070,
            "title": "Immune response to the 10 PHiD-CV polysaccharide conjugates"
        },
        {
            "endOffset": 34271,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 34091,
                    "startOffset": 34086
                },
                "b0040": {
                    "endOffset": 34270,
                    "startOffset": 34264
                },
                "b0045": {
                    "endOffset": 34270,
                    "startOffset": 34264
                },
                "b0050": {
                    "endOffset": 34270,
                    "startOffset": 34264
                }
            },
            "secId": "s0005",
            "sentence": "Recently, new formulations containing highly conserved pneumococcal proteins such as pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD) have been in development [7,8] and have the potential to offer protection against a wider spectrum of pneumococcal serotypes and prevent serotype emergence and replacement in nasopharyngeal colonisation [8\u201310].",
            "startOffset": 33900,
            "title": "Introduction"
        },
        {
            "endOffset": 41523,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Pneumococcal serotype-specific IgG antibodies were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F (assay cut-off: 0.05 \u00b5g/mL).",
            "startOffset": 41306,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 59326,
            "parents": [],
            "secId": "s0085",
            "sentence": "Reactogenicity assessment for co-administered vaccines was performed only after vaccination visits where pneumococcal vaccines were administered, e.g. it was not done for measles and yellow fever vaccines given at 10 months of age in 3+0 groups, and post-dose 2 of DTPw-HBV/Hib vaccine for the 2+1 groups since no pneumococcal vaccine was co-administered.",
            "startOffset": 58971,
            "title": "Discussion"
        },
        {
            "endOffset": 51991,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The observed anti-diphtheria GMC tended to be lower in the PCV13 group compared to the other groups.",
            "startOffset": 51891,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 56890,
            "parents": [],
            "secId": "s0085",
            "sentence": "It has to be noted, however, that our study was not designed for such inter-group comparisons and these findings should be interpreted with caution, especially considering that many factors could play a role (e.g. size and quantity of the PSs, protein carriers and conjugation methods, manufacturing process) and influence antibody functionality.",
            "startOffset": 56544,
            "title": "Discussion"
        },
        {
            "endOffset": 37195,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Randomisation was performed using MATEX, a block randomisation program developed for use in Statistical Analysis System by GSK.",
            "startOffset": 37068,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 60608,
            "parents": [],
            "secId": "s0095",
            "sentence": "Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.",
            "startOffset": 60473,
            "title": "Data sharing statement"
        },
        {
            "endOffset": 40696,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 40331,
                    "startOffset": 40327
                }
            },
            "secId": "s0030",
            "sentence": "In addition to previously reported objectives [16], study objectives included evaluation of immune responses to the components of the investigational vaccines, other than the pneumococcal protein antigens, and co-administered vaccines, and occurrence of local solicited adverse events at co-administered vaccine injection site (pain, redness, and swelling at injection site) within 4 days (days 0\u20133) post-each dose.",
            "startOffset": 40281,
            "title": "Study objectives"
        },
        {
            "endOffset": 60779,
            "parents": [],
            "secId": "s0100",
            "sentence": "Prevenar 13/Prevnar 13 is a trademark of Pfizer Inc.",
            "startOffset": 60727,
            "title": "Trademark statement"
        },
        {
            "endOffset": 42592,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immune responses were evaluated 1 month post-dose 3 for the DTPw-HBV/Hib and OPV vaccines, and 3 months after administration of measles and yellow fever vaccines.",
            "startOffset": 42430,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 36107,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were healthy infants aged 8\u201310 weeks at study start.",
            "startOffset": 36042,
            "title": "Study design and participants"
        },
        {
            "endOffset": 51685,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Increases in anti-protein D GMCs were observed post-vaccination in all groups receiving a protein D-containing vaccine when compared to pre-vaccination levels, regardless of the presence of dPly and PhtD.",
            "startOffset": 51481,
            "title": "Immune response against protein D"
        },
        {
            "endOffset": 46537,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 46536,
                    "startOffset": 46532
                }
            },
            "secId": "s0055",
            "sentence": "Reasons for withdrawals have been previously published [16].",
            "startOffset": 46477,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 42933,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibodies against the whole cell B. pertussis antigens were determined by ELISA using the IgG enzyme immunoassay test kit from Labsystems (cut-off: 15 EL.U/mL).",
            "startOffset": 42772,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 64252,
            "parents": [],
            "secId": "s0110",
            "sentence": "VV is the inventor of some pending patents owned by the GSK group of companies in the pneumococcal vaccine field.",
            "startOffset": 64139,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 41773,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 41772,
                    "startOffset": 41768
                }
            },
            "secId": "s0035",
            "sentence": "Immune responses were described in terms of percentages of infants with IgG concentrations \u22650.2 \u00b5g/mL (equivalent to antibody concentrations \u22650.35 \u00b5g/mL measured by the non-22F ELISA of the World Health Organization [WHO] reference laboratory) [18].",
            "startOffset": 41524,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 58970,
            "parents": [],
            "secId": "s0085",
            "sentence": "Thus, results for those antigens should be interpreted with caution as they may not reflect only study vaccination.",
            "startOffset": 58855,
            "title": "Discussion"
        },
        {
            "endOffset": 59820,
            "parents": [],
            "secId": "s0085",
            "sentence": "No differences were observed in the immune responses to DTPw-HBV/Hib, OPV, measles and yellow fever vaccines used for infant EPI vaccinations in The Gambia, and reported reactogenicity rates for co-administered vaccines were also comparable between groups.",
            "startOffset": 59564,
            "title": "Discussion"
        },
        {
            "endOffset": 63916,
            "parents": [],
            "secId": "s0110",
            "sentence": "BMG reports a grant from PATH to the LSHTM to support the study.",
            "startOffset": 63852,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 36935,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "We randomly selected 50% of participants (100 per group) for analysis of opsonophagocytic activity (OPA) (OPA subset).",
            "startOffset": 36817,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 54219,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 54218,
                    "startOffset": 54211
                },
                "b0110": {
                    "endOffset": 54218,
                    "startOffset": 54211
                },
                "b0115": {
                    "endOffset": 54218,
                    "startOffset": 54211
                },
                "b0120": {
                    "endOffset": 54218,
                    "startOffset": 54211
                }
            },
            "secId": "s0085",
            "sentence": "Efficacy/effectiveness data of PHiD-CV have been reported for various clinical trials and post-marketing surveillance studies [21\u201324].",
            "startOffset": 54085,
            "title": "Discussion"
        },
        {
            "endOffset": 64138,
            "parents": [],
            "secId": "s0110",
            "sentence": "KD was employed by and owns shares of the GSK group of companies.",
            "startOffset": 64073,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 53727,
            "parents": [],
            "secId": "s0085",
            "sentence": "Our study evaluated the serotype-specific immune responses to pneumococcal PS conjugates when combined in investigational formulations with pneumococcal proteins dPly and PhtD, as well as the immune response and reactogenicity to the co-administered EPI vaccines.",
            "startOffset": 53464,
            "title": "Discussion"
        },
        {
            "endOffset": 43968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Injection site symptoms (pain, redness, and swelling) were collected using diary cards within 4 days post-each dose.",
            "startOffset": 43852,
            "title": "Reactogenicity assessment"
        },
        {
            "endOffset": 63677,
            "parents": [],
            "secId": "s0110",
            "sentence": "MAn, EOO, YS, PKO, AW, OTI, OO, and MAl have no conflicts of interest to disclose.",
            "startOffset": 63595,
            "title": "Conflict of interests"
        },
        {
            "endOffset": 38238,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "PHiD-CV is a suspension of 1 \u00b5g of PS for serotypes 1, 5, 6B, 7F, 9V, 14 and 23F and 3 \u00b5g for serotype 4 conjugated to protein D, 3 \u00b5g of PS for serotype 18C conjugated to tetanus toxoid, and 3 \u00b5g of PS for serotype 19F conjugated to diphtheria toxoid.",
            "startOffset": 37986,
            "title": "Study vaccines"
        },
        {
            "endOffset": 44587,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Trained field workers working under the supervision of the principal investigator visited each vaccinated child on days 1, 2, and 3 following each vaccine dose to collect information on any AEs and to record any medication taken.",
            "startOffset": 44358,
            "title": "Reactogenicity assessment"
        },
        {
            "endOffset": 52620,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Three months post-vaccination, 72.9\u201385.6% of children in the 3+0 groups and 82.3\u201384.0% of children in the 2+1 groups had antibody levels equal to or above the seroprotective level for measles, and 96.9\u2013100% and 95.8\u201397.9%, respectively, were considered seroprotected against yellow fever (Table 4).",
            "startOffset": 52322,
            "title": "Immune response to the co-administered vaccines"
        },
        {
            "endOffset": 45114,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 45113,
                    "startOffset": 45109
                }
            },
            "secId": "s0045",
            "sentence": "A target sample size of 170 evaluable participants per group was driven by confirmatory objectives (a sample size of 200 participants per group allowed detection of a 35% reduction in non-PHiD-CV serotypes or serogroups carriage prevalence with 82% power, assuming that non-PHiD-CV serotypes or serogroups carriage prevalence in the comparator PHiD-CV group was 40%; results were previously presented) [16].",
            "startOffset": 44707,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 56279,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 56278,
                    "startOffset": 56274
                }
            },
            "secId": "s0085",
            "sentence": "Another study with PHiD-CV and DTPw-HBV/Hib (Tritanrix-HepB/Hib) co-administration in an African setting also reported pain as the most frequent injection site symptom for observations combined for PHiD-CV and DTPw-HBV/Hib injection sites, but injection site swelling was rare and no redness or grade 3 injection site symptoms were reported [26].",
            "startOffset": 55933,
            "title": "Discussion"
        },
        {
            "endOffset": 37351,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Treatment allocation for pneumococcal vaccines at the investigator site was performed with an internet randomisation system using a minimisation procedure.",
            "startOffset": 37196,
            "title": "Randomisation and blinding"
        },
        {
            "endOffset": 62900,
            "parents": [],
            "secId": "s0105",
            "sentence": "KS was involved in the generation of study data and in the interpretation of the results.",
            "startOffset": 62811,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 43281,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody concentrations against the Hib polysaccharide PRP were measured by ELISA (cut-off: 0.15 \u03bcg/mL; this was also the cut-off for seroprotection).",
            "startOffset": 43131,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 60246,
            "parents": [],
            "secId": "s0090",
            "sentence": "GlaxoSmithKline Biologicals SA designed the study in collaboration with PATH, London School of Hygiene & Tropical Medicine (LSHTM), and the Medical Research Council (MRC) investigators, and coordinated collection, analysis, and interpretation of data.",
            "startOffset": 59995,
            "title": "Funding"
        }
    ],
    "docId": "S0264410X1930355X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "aderonke.odutola@lshtm.ac.uk",
                "first": "Aderonke",
                "initial": "A.",
                "last": "Odutola"
            },
            {
                "email": "martin.x.ota@gsk.com",
                "first": "Martin O.C.",
                "initial": "M.O.C.",
                "last": "Ota"
            },
            {
                "email": "mantonio@mrc.gm",
                "first": "Martin",
                "initial": "M.",
                "last": "Antonio"
            },
            {
                "email": "tundeyogundare@yahoo.com",
                "first": "Ezra O.",
                "initial": "E.O.",
                "last": "Ogundare"
            },
            {
                "email": "ysaidu@clintonhealthaccess.org",
                "first": "Yauba",
                "initial": "Y.",
                "last": "Saidu"
            },
            {
                "email": "pkowiafe@uhas.edu.gh",
                "first": "Patrick K.",
                "initial": "P.K.",
                "last": "Owiafe"
            },
            {
                "email": "aworwui@mrc.gm",
                "first": "Archibald",
                "initial": "A.",
                "last": "Worwui"
            },
            {
                "email": "oidoko@mrc.gm",
                "first": "Olubukola T.",
                "initial": "O.T.",
                "last": "Idoko"
            },
            {
                "email": "oowolabi@mrc.gm",
                "first": "Olumuyiwa",
                "initial": "O.",
                "last": "Owolabi"
            },
            {
                "email": "bkampmann@mrc.gm",
                "first": "Beate",
                "initial": "B.",
                "last": "Kampmann"
            },
            {
                "email": "Brian.Greenwood@lshtm.ac.uk",
                "first": "Brian M.",
                "initial": "B.M.",
                "last": "Greenwood"
            },
            {
                "email": "malderson@path.org",
                "first": "Mark",
                "initial": "M.",
                "last": "Alderson"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "kristien.m.swinnen@gsk.com",
                "first": "Kristien",
                "initial": "K.",
                "last": "Swinnen"
            },
            {
                "email": "vincent.verlant@gsk.com",
                "first": "Vincent",
                "initial": "V.",
                "last": "Verlant"
            },
            {
                "email": "dobbelaerekurt@gmail.com",
                "first": "Kurt",
                "initial": "K.",
                "last": "Dobbelaere"
            },
            {
                "email": "dorota.d.borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.03.033",
        "firstpage": "2586",
        "issn": "0264410X",
        "keywords": [
            "Immunogenicity",
            "Paediatric vaccination",
            "Pneumococcal protein-containing vaccine",
            "Pneumococcal serotype-specific polysaccharide",
            "Streptococcus pneumoniae"
        ],
        "lastpage": "2599",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines \u2013 A phase II, randomised, observer-blind study in Gambian infants"
    }
}